{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:14:16Z","timestamp":1780524856884,"version":"3.54.1"},"reference-count":249,"publisher":"Elsevier","isbn-type":[{"value":"9780323901642","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009307","name":"Parkinson Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012479","name":"Weston Brain Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.pbr.2022.01.013","type":"book-chapter","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T08:10:32Z","timestamp":1643962232000},"page":"373-403","source":"Crossref","is-referenced-by-count":28,"title":["Cognition and serotonin in Parkinson's disease"],"prefix":"10.1016","member":"78","reference":[{"issue":"5","key":"10.1016\/bs.pbr.2022.01.013_bb0010","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.56.5.595","article-title":"Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study","volume":"56","author":"Aarsland","year":"1999","journal-title":"Arch. Neurol."},{"issue":"10","key":"10.1016\/bs.pbr.2022.01.013_bb0015","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/gps.949","article-title":"Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia","volume":"18","author":"Aarsland","year":"2003","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"15","key":"10.1016\/bs.pbr.2022.01.013_bb0020","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/mds.22589","article-title":"Neuropsychiatric symptoms in Parkinson's disease","volume":"24","author":"Aarsland","year":"2009","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0025","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1085\/jgp.201511389","article-title":"Revisiting the role of raphe and serotonin in neuropsychiatric disorders","volume":"145","author":"Adell","year":"2015","journal-title":"J. Gen. Physiol."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0030","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/0014-4886(65)90061-0","article-title":"Efferent connections of the substantia nigra in the cat","volume":"11","author":"Afifi","year":"1965","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0035","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/syn.20109","article-title":"Modulation of dopamine release by striatal 5-HT2C receptors","volume":"55","author":"Alex","year":"2005","journal-title":"Synapse"},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0040","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.2337\/db16-0755","article-title":"Glucagon-like peptide 1 and its analogs act in the dorsal raphe and modulate central serotonin to reduce appetite and body weight","volume":"66","author":"Anderberg","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/bs.pbr.2022.01.013_bb0045","series-title":"Handbook of Behavioral Neuroscience","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-7339(10)70080-1","article-title":"CHAPTER 2.5 - cellular effects of serotonin in the CNS","author":"Andrade","year":"2010"},{"issue":"6","key":"10.1016\/bs.pbr.2022.01.013_bb0050","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/bs.pbr.2022.01.013_bb0055","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1364-6613(98)01240-6","article-title":"Catecholamine modulation of prefrontal cortical cognitive function","volume":"2","author":"Arnsten","year":"1998","journal-title":"Trends Cogn. Sci."},{"issue":"8","key":"10.1016\/bs.pbr.2022.01.013_bb0060","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1046\/j.1460-9568.1999.00708.x","article-title":"A pre-and postsynaptic modulatory action of 5-HT and the 5-HT2A, 2C receptor agonist DOB on NMDA-evoked responses in the rat medial prefrontal cortex","volume":"11","author":"Arvanov","year":"1999","journal-title":"Eur. J. Neurosci."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0065","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1471-4159.1992.tb09752.x","article-title":"Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases","volume":"58","author":"Aubert","year":"1992","journal-title":"J. Neurochem."},{"issue":"6","key":"10.1016\/bs.pbr.2022.01.013_bb0070","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0075","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J. Parkinsons Dis."},{"issue":"6","key":"10.1016\/bs.pbr.2022.01.013_bb0080","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00213-018-5154-7","article-title":"Anti-inflammatory and antinociceptive activities of glucagon-like peptides: evaluation of their actions on serotonergic, nitrergic, and opioidergic systems","volume":"236","author":"Aykan","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0085","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in Parkinson disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Arch. Neurol."},{"issue":"1\u20132","key":"10.1016\/bs.pbr.2022.01.013_bb0090","first-page":"35","article-title":"Morphological alterations of the synapses in the locus coeruleus in Parkinson's disease","volume":"248","author":"Baloyannis","year":"2006","journal-title":"Comparative Study"},{"issue":"8","key":"10.1016\/bs.pbr.2022.01.013_bb0095","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0100","first-page":"108","article-title":"Attentional deficits in Parkinson's disease: partial reversibility with anphtoxazine (SDZ NVI-085), a selective noradrenergic \u03b1\u2081 agonist","volume":"21","author":"B\u00e9dard","year":"1998","journal-title":"Clin. Neuropharmacol."},{"issue":"17","key":"10.1016\/bs.pbr.2022.01.013_bb0105","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1021\/jm5003952","article-title":"Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease","volume":"57","author":"Benham\u00fa","year":"2014","journal-title":"J. Med. Chem."},{"issue":"771","key":"10.1016\/bs.pbr.2022.01.013_bb0110","article-title":"Vortioxetine for cognitive enhancement in major depression: from animal models to clinical research","volume":"10","author":"Bennabi","year":"2019","journal-title":"Front Psychiatry"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0115","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1460-9568.2002.02072.x","article-title":"Differential modulation of Ih by 5-HT receptors in mouse CA1 hippocampal neurons","volume":"16","author":"Bickmeyer","year":"2002","journal-title":"Eur. J. Neurosci."},{"issue":"5","key":"10.1016\/bs.pbr.2022.01.013_bb0120","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tins.2007.03.006","article-title":"Dopamine neuron systems in the brain: an update","volume":"30","author":"Bj\u00f6rklund","year":"2007","journal-title":"Trends Neurosci."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1476-5381.1993.tb13433.x","article-title":"Functional characterization of a 5-HT3 receptor which modulates the release of 5-HT in the Guinea-pig brain","volume":"108","author":"Blier","year":"1993","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0130","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.bbr.2009.12.048","article-title":"The cholinergic system and Parkinson disease","volume":"221","author":"Bohnen","year":"2011","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0135","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00415-005-0971-0","article-title":"Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia","volume":"253","author":"Bohnen","year":"2006","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/bs.pbr.2022.01.013_bb0140","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/jcbfm.2012.60","article-title":"Heterogeneity of cholinergic denervation in Parkinson's disease without dementia","volume":"32","author":"Bohnen","year":"2012","journal-title":"J. Cereb. Blood Flow Metab."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0145","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0022-3565(25)10539-9","article-title":"Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides","volume":"274","author":"Bourson","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0306-4522(87)90008-X","article-title":"A detailed mapping of dopamine D-2 receptors in rat central nervous system by autoradiography with [125I] iodosulpride","volume":"20","author":"Bouthenet","year":"1987","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson's disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00702-004-0193-0","article-title":"Pergolide effect on cognitive functions in early-mild Parkinson's disease","volume":"112","author":"Brusa","year":"2005","journal-title":"J. Neural Transm. (Vienna)"},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0165","first-page":"13","article-title":"The effect of dopamine agonists on cognitive functions in non-demented early-mild Parkinson's disease patients","volume":"28","author":"Brusa","year":"2013","journal-title":"Funct. Neurol."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0170","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.bbr.2007.10.008","article-title":"Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl\/6j mice","volume":"187","author":"Cachard-Chastel","year":"2008","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0175","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.dcn.2011.04.003","article-title":"Atomoxetine facilitates attentional set shifting in adolescent rats","volume":"1","author":"Cain","year":"2011","journal-title":"Dev. Cogn. Neurosci."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0180","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0022-510X(83)90045-X","article-title":"Pathological changes in the nucleus of Meynert in Alzheimer's and Parkinson's diseases","volume":"59","author":"Candy","year":"1983","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0185","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1212\/WNL.37.1.42","article-title":"Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus","volume":"37","author":"Cash","year":"1987","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/bs.pbr.2022.01.013_bb0190","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.biopsych.2007.03.003","article-title":"Atomoxetine improved response inhibition in adults with attention deficit\/hyperactivity disorder","volume":"62","author":"Chamberlain","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/bs.pbr.2022.01.013_bb0195","doi-asserted-by":"crossref","first-page":"107839","DOI":"10.1016\/j.neuropharm.2019.107839","article-title":"The 5-HT6 receptor interactome: new insight in receptor signaling and its impact on brain physiology and pathologies","volume":"172","author":"Chaumont-Dubel","year":"2020","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0200","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00023210-200418030-00004","article-title":"Quetiapine. A review of its use in the management of schizophrenia","volume":"18","author":"Cheer","year":"2004","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0205","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1749-6632.1998.tb10229.x","article-title":"Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex","volume":"861","author":"Chen","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/bs.pbr.2022.01.013_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2018.05.027","article-title":"5-HT6 receptor agonist and memory-enhancing properties of hypidone hydrochloride (YL-0919), a novel 5-HT1A receptor partial agonist and SSRI","volume":"138","author":"Chen","year":"2018","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/bs.pbr.2022.01.013_bb0215","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1002\/mdc3.12466","article-title":"The relationship between serotonin-2A receptor and cognitive functions in nondemented Parkinson's disease patients with visual hallucinations","volume":"4","author":"Cho","year":"2017","journal-title":"Mov. Disord. Clin. Pract."},{"issue":"7","key":"10.1016\/bs.pbr.2022.01.013_bb0220","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.neurobiolaging.2010.11.015","article-title":"Volumetric analysis of the substantia innominata in patients with Parkinson's disease according to cognitive status","volume":"33","author":"Choi","year":"2012","journal-title":"Neurobiol. Aging"},{"issue":"5672","key":"10.1016\/bs.pbr.2022.01.013_bb0225","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1126\/science.1094987","article-title":"Cognitive inflexibility after prefrontal serotonin depletion","volume":"304","author":"Clarke","year":"2004","journal-title":"Science"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0230","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1212\/WNL.0000000000002839","article-title":"Cholinergic and perfusion brain networks in Parkinson disease dementia","volume":"87","author":"Colloby","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0235","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase inhibitors: pharmacology and toxicology","volume":"11","author":"Colovi\u0107","year":"2013","journal-title":"Curr. Neuropharmacol."},{"issue":"7","key":"10.1016\/bs.pbr.2022.01.013_bb0240","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1007\/s00429-015-1176-7","article-title":"Ascending serotonin neuron diversity under two umbrellas","volume":"221","author":"Commons","year":"2016","journal-title":"Brain Struct. Funct."},{"issue":"10","key":"10.1016\/bs.pbr.2022.01.013_bb0245","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1097\/00001756-199406020-00018","article-title":"5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex","volume":"5","author":"Consolo","year":"1994","journal-title":"Neuroreport"},{"issue":"12","key":"10.1016\/bs.pbr.2022.01.013_bb0250","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/brain\/124.12.2503","article-title":"Mechanisms of cognitive set flexibility in Parkinson's disease","volume":"124","author":"Cools","year":"2001","journal-title":"Brain"},{"issue":"12","key":"10.1016\/bs.pbr.2022.01.013_bb0255","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/cercor\/11.12.1136","article-title":"Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands","volume":"11","author":"Cools","year":"2001","journal-title":"Cereb. Cortex"},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0260","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awf052","article-title":"Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET","volume":"125","author":"Cools","year":"2002","journal-title":"Brain"},{"key":"10.1016\/bs.pbr.2022.01.013_bb0265","first-page":"43","article-title":"Alpha (2)-adrenoceptors in the treatment of dementia: an attentional mechanism?","volume":"10","author":"Coull","year":"1996","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/bs.pbr.2022.01.013_bb0270","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0361-9230(02)00967-X","article-title":"Potentiation of amphetamine-induced changes in dopamine and 5-HT by a 5-HT6 receptor antagonist","volume":"59","author":"Dawson","year":"2003","journal-title":"Brain Res. Bull."},{"issue":"26","key":"10.1016\/bs.pbr.2022.01.013_bb0275","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.2174\/1381612821666150605112105","article-title":"5-HT6 receptor antagonists: potential efficacy for the treatment of cognitive impairment in schizophrenia","volume":"21","author":"de Bruin","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/bs.pbr.2022.01.013_bb0280","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neuropharm.2017.07.010","article-title":"Antagonism of the 5-HT6 receptor \u2013 preclinical rationale for the treatment of Alzheimer's disease","volume":"125","author":"de Jong","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/bs.pbr.2022.01.013_bb0285","first-page":"561046","article-title":"Frontostriatal cognitive staging in Parkinson's disease","volume":"2012","author":"de la Fuente-Fern\u00e1ndez","year":"2012","journal-title":"Parkinson's Dis."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.119.260281","article-title":"SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action","volume":"371","author":"Dedic","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/bs.pbr.2022.01.013_bb0295","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/npp.2013.313","article-title":"Stimulation of 5-HT 2C receptors improves cognitive deficits induced by human tryptophan hydroxylase 2 loss of function mutation","volume":"39","author":"Del'Guidice","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/bs.pbr.2022.01.013_bb0300","doi-asserted-by":"crossref","first-page":"147493","DOI":"10.1016\/j.brainres.2021.147493","article-title":"NLX-101, a cortical 5-HT1A receptor biased agonist, reverses scopolamine-induced deficit in the delayed non-matching to position model of cognition","volume":"1765","author":"Depoortere","year":"2021","journal-title":"Brain Res."},{"issue":"25","key":"10.1016\/bs.pbr.2022.01.013_bb0305","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.2174\/092986706778521805","article-title":"Serotonin involvement in the basal ganglia pathophysiology: could the 5-HT2C receptor be a new target for therapeutic strategies?","volume":"13","author":"Di Giovanni","year":"2006","journal-title":"Curr. Med. Cem."},{"key":"10.1016\/bs.pbr.2022.01.013_bb0310","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.nlm.2013.04.002","article-title":"Chronic treatment with the serotonin 2A\/2C receptor antagonist SR 46349B enhances the retention and efficiency of rule-guided behavior in mice","volume":"103","author":"Dougherty","year":"2013","journal-title":"Neurobiol. Learn. Mem."},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0315","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0006-8993(78)91077-6","article-title":"The dorsal and medial raphe projections to the substantia nigra in the rat: electrophysiological, biochemical and behavioural observations","volume":"151","author":"Dray","year":"1978","journal-title":"Brain Res."},{"issue":"24","key":"10.1016\/bs.pbr.2022.01.013_bb0320","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa041470","article-title":"Rivastigmine for dementia associated with Parkinson's disease","volume":"351","author":"Emre","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/bs.pbr.2022.01.013_bb0325","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/mds.26048","article-title":"Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement","volume":"29","author":"Espay","year":"2014","journal-title":"Mov. Disord."},{"issue":"1\u20132","key":"10.1016\/bs.pbr.2022.01.013_bb0330","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","article-title":"Epidemiology of psychosis in Parkinson's disease","volume":"289","author":"F\u00e9nelon","year":"2010","journal-title":"J. Neurol. Sci."},{"issue":"Pt 4","key":"10.1016\/bs.pbr.2022.01.013_bb0335","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/brain\/123.4.733","article-title":"Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors","volume":"123","author":"Fenelon","year":"2000","journal-title":"Brain"},{"issue":"6","key":"10.1016\/bs.pbr.2022.01.013_bb0340","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/mds.22839","article-title":"The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria","volume":"25","author":"F\u00e9nelon","year":"2010","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0345","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40263-016-0399-3","article-title":"Serotonin 5-HT6 receptor antagonists in Alzheimer's disease: therapeutic rationale and current development status","volume":"31","author":"Ferrero","year":"2017","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0350","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40263-016-0399-3","article-title":"Serotonin 5-HT(6) receptor antagonists in Alzheimer's disease: therapeutic rationale and current development status","volume":"31","author":"Ferrero","year":"2017","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/bs.pbr.2022.01.013_bb0355","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/0306-4522(77)90120-8","article-title":"An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the rat","volume":"2","author":"Fibiger","year":"1977","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0360","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/gps.998","article-title":"A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil","volume":"19","author":"Finkel","year":"2004","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"8","key":"10.1016\/bs.pbr.2022.01.013_bb0365","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/archneurol.2010.166","article-title":"A 12-year population-based study of psychosis in Parkinson disease","volume":"67","author":"Forsaa","year":"2010","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0370","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1037\/0894-4105.14.2.247","article-title":"Working memory functioning in medicated Parkinson's disease patients and the effect of withdrawal of dopaminergic medication","volume":"14","author":"Fournet","year":"2000","journal-title":"Neuropsychology"},{"issue":"6","key":"10.1016\/bs.pbr.2022.01.013_bb0375","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/1531-8257(200011)15:6<1064::AID-MDS1002>3.0.CO;2-C","article-title":"5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease","volume":"15","author":"Fox","year":"2000","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/bs.pbr.2022.01.013_bb0380","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/mds.26285","article-title":"Default mode network links to visual hallucinations: a comparison between Parkinson's disease and multiple system atrophy","volume":"30","author":"Franciotti","year":"2015","journal-title":"Mov. Disord."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0385","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0028-3908(01)00165-4","article-title":"5-HT6 receptor antagonism potentiates the behavioral and neurochemical effects of amphetamine but not cocaine","volume":"42","author":"Frantz","year":"2002","journal-title":"Neuropharmacology"},{"issue":"Pt 5","key":"10.1016\/bs.pbr.2022.01.013_bb0390","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1093\/brain\/114.5.2253","article-title":"Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease","volume":"114","author":"Gai","year":"1991","journal-title":"Brain"},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0395","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0022-3565(24)37700-6","article-title":"Role of 5-HT4 receptors in the mouse passive avoidance test","volume":"286","author":"Galeotti","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0400","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/(SICI)1098-2396(20000315)35:4<281::AID-SYN6>3.0.CO;2-A","article-title":"Dorsal raphe stimulation differentially modulates dopaminergic neurons in the ventral tegmental area and substantia nigra","volume":"35","author":"Gervais","year":"2000","journal-title":"Synapse"},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0405","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-3565(24)37512-3","article-title":"Serotonergic modulation of acetylcholine release from cortex of freely moving rats","volume":"285","author":"Giovannini","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0410","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/(SICI)1098-2396(20000601)36:3<205::AID-SYN5>3.0.CO;2-D","article-title":"Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat","volume":"36","author":"Gobert","year":"2000","journal-title":"Synapse"},{"key":"10.1016\/bs.pbr.2022.01.013_bb0415","first-page":"675630","article-title":"New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges","volume":"2011","author":"Goldman","year":"2011","journal-title":"Parkinson's Dis."},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0420","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11940-013-0281-2","article-title":"Treatment of psychosis and dementia in Parkinson's disease","volume":"16","author":"Goldman","year":"2014","journal-title":"Curr. Treat. Options. Neurol."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0425","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cger.2020.01.001","article-title":"Cognitive impairment and dementia in Parkinson disease","volume":"36","author":"Goldman","year":"2020","journal-title":"Clin. Geriatr. Med."},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0430","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1124\/jpet.107.133165","article-title":"Characterization of the molecular fragment that is responsible for agonism of pergolide at serotonin 5-hydroxytryptamine2B and 5-hydroxytryptamine2A receptors","volume":"324","author":"G\u00f6rnemann","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0435","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/archneur.63.4.584","article-title":"Motor score of the unified Parkinson disease rating scale as a good predictor of Lewy body\u2013associated neuronal loss in the substantia nigra","volume":"63","author":"Greffard","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/bs.pbr.2022.01.013_bb0440","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3389\/fnins.2018.00770","article-title":"Default mode network complexity and cognitive decline in mild Alzheimer's disease","volume":"12","author":"Grieder","year":"2018","journal-title":"Front. Neurosci."},{"issue":"6","key":"10.1016\/bs.pbr.2022.01.013_bb0445","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/mds.27665","article-title":"Modifiable risk factors for cognitive impairment in Parkinson's disease: a systematic review and meta-analysis of prospective cohort studies","volume":"34","author":"Guo","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.pbr.2022.01.013_bb0450","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0079-6123(08)63823-6","article-title":"Central noradrenergic neurons: the autonomic connection","volume":"88","author":"Guyenet","year":"1991","journal-title":"J. Prog. Brain Res."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0455","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/syn.890200109","article-title":"Pre- and post-synaptic effects of the 5-HT3 agonist 2-Methyl-5-HT on the 5-HT system in the rat brain","volume":"20","author":"Haddjeri","year":"1995","journal-title":"Synapse"},{"key":"10.1016\/bs.pbr.2022.01.013_bb0460","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.nlm.2016.06.014","article-title":"The serotonergic 5-HT4 receptor: a unique modulator of hippocampal synaptic information processing and cognition","volume":"138","author":"Hagena","year":"2017","journal-title":"Neurobiol. Learn. Mem."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0465","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.expneurol.2005.01.013","article-title":"Oxidative stress and inflammation in Parkinson's disease: is there a causal link?","volume":"193","author":"Hald","year":"2005","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0470","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00213-010-2089-z","article-title":"Functional topography of midbrain and pontine serotonergic systems: implications for synaptic regulation of serotonergic circuits","volume":"213","author":"Hale","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"issue":"8","key":"10.1016\/bs.pbr.2022.01.013_bb0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1002237","article-title":"Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee","volume":"7","author":"Hamza","year":"2011","journal-title":"PLoS Genet."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0480","first-page":"27","article-title":"MR analysis of the substantia Innominata in Normal aging","volume":"23","author":"Hanyu","year":"2002","journal-title":"Alzheimer Disease, and Other Types of Dementia."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0485","first-page":"245","article-title":"The 5-HI1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset","volume":"127","author":"Harder","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0490","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cne.903250107","article-title":"Cholinergic innervation of the human thalamus: dual origin and differential nuclear distribution","volume":"325","author":"Heckers","year":"1992","journal-title":"J. Comp. Neurol."},{"issue":"16","key":"10.1016\/bs.pbr.2022.01.013_bb0495","doi-asserted-by":"crossref","first-page":"5976","DOI":"10.1073\/pnas.84.16.5976","article-title":"Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy","volume":"84","author":"Hirsch","year":"1987","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0500","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/jpet.107.133082","article-title":"Correlating efficacy in rodent cognition models with in vivo 5-hydroxytryptamine1a receptor occupancy by a novel antagonist, (R)-N-(2-methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane carboxamide (WAY-101405)","volume":"325","author":"Hirst","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/bs.pbr.2022.01.013_bb0505","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/jnnp.70.6.734","article-title":"Prospective study of hallucinations and delusions in Parkinson's disease","volume":"70","author":"Holroyd","year":"2001","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0510","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ana.410360209","article-title":"Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits","volume":"36","author":"Holthoff","year":"1994","journal-title":"Ann. Neurol."},{"key":"10.1016\/bs.pbr.2022.01.013_bb0515","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/archneur.1997.00550140025008","article-title":"Functional effects of striatal dysfunction in Parkinson\u2018s disease","volume":"54","author":"Holthoff-Detto","year":"1997","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0520","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0006-8993(94)91329-3","article-title":"Serotonergic synaptic input to cholinergic neurons in the rat mesopontine tegmentum","volume":"647","author":"Honda","year":"1994","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0525","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.bbr.2011.01.034","volume":"220","author":"Horisawa","year":"2011","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0530","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jchemneu.2003.10.002","article-title":"The human raphe nuclei and the serotonergic system","volume":"26","author":"Hornung","year":"2003","journal-title":"J. Chem. Neuroanat."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0535","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/cne.903200404","article-title":"The selective innervation by serotoninergic axons of calbindin-containing interneurons in the neocortex and hippocampus of the marmoset","volume":"320","author":"Hornung","year":"1992","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/bs.pbr.2022.01.013_bb0540","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3389\/fnagi.2016.00247","article-title":"Dysfunction of the default mode network in drug-Na\u00efve Parkinson's disease with mild cognitive impairments: a resting-state fMRI study","volume":"8","author":"Hou","year":"2016","journal-title":"Front. Aging Neurosci."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0545","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S1607-551X(08)70117-7","article-title":"Cognitive and motor components of response speed in the Stroop test in Parkinson's disease patients","volume":"24","author":"Hsieh","year":"2008","journal-title":"Kaohsiung J. Med. Sci."},{"issue":"10","key":"10.1016\/bs.pbr.2022.01.013_bb0550","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1007\/s00213-018-4972-y","article-title":"5-HT1A parital agonism and 5-HT7 antagonism restore episodic memory in subchronic phencyclidine-treated mice: role of brain glutamate, dopamine, acetylcholine and GABA","volume":"235","author":"Huang","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"issue":"10","key":"10.1016\/bs.pbr.2022.01.013_bb0555","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/mds.23083","article-title":"Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations","volume":"25","author":"Huot","year":"2010","journal-title":"Mov. Disord."},{"issue":"21","key":"10.1016\/bs.pbr.2022.01.013_bb0560","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215340","article-title":"Serotonin 5-HT(4) receptor agonists improve facilitation of contextual fear extinction in an MPTP-induced mouse model of Parkinson's disease","volume":"20","author":"Ishii","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.pbr.2022.01.013_bb0565","doi-asserted-by":"crossref","first-page":"104608","DOI":"10.1016\/j.neuint.2019.104608","article-title":"Dopaminergic neuroprotective effects of rotigotine via 5-HT1A receptors: possibly involvement of metallothionein expression in astrocytes","volume":"132","author":"Isooka","year":"2020","journal-title":"Neurochem. Int."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0570","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1152\/physrev.1992.72.1.165","article-title":"Structure and function of the brain serotonin system","volume":"72","author":"Jacobs","year":"1992","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0575","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00415-011-6149-z","article-title":"The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study","volume":"259","author":"Janzen","year":"2012","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0580","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/jnnp.51.4.540","article-title":"The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease","volume":"51","author":"Jellinger","year":"1988","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/bs.pbr.2022.01.013_bb0585","series-title":"Cognitive Screening Instruments: A Practical Approach","article-title":"Montreal cognitive assessment (MoCA): concept and clinical review","author":"Julayanont","year":"2017"},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0590","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00279662","article-title":"Projections from the ventral tegmental area and mesencephalic raphe to the dorsal raphe nucleus in the rat","volume":"73","author":"Kalen","year":"1988","journal-title":"Exp. Brain Res."},{"key":"10.1016\/bs.pbr.2022.01.013_bb0595","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/CIA.S129145","article-title":"Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia","volume":"12","author":"Kandiah","year":"2017","journal-title":"Clin. Interv. Aging"},{"issue":"7","key":"10.1016\/bs.pbr.2022.01.013_bb0600","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.euroneuro.2010.03.003","article-title":"The selective 5-HT1A receptor antagonist NAD-299 increases acetylcholine release but not extracellular glutamate levels in the frontal cortex and hippocampus of awake rat","volume":"20","author":"Kehr","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/bs.pbr.2022.01.013_bb0605","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/archneur.60.9.1223","article-title":"Positron emission tomography of striatal serotonin transporters in Parkinson disease","volume":"60","author":"Kerenyi","year":"2003","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/bs.pbr.2022.01.013_bb0610","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/13543784.2018.1483334","article-title":"The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update","volume":"27","author":"Khoury","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0615","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/(SICI)1096-9861(19960205)365:2<289::AID-CNE7>3.0.CO;2-1","article-title":"Immunocytochemical localization of serotonin1A receptors in the rat central nervous system","volume":"365","author":"Kia","year":"1996","journal-title":"J. Comp. Neurol."},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0620","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF00168686","article-title":"Effects of 5-HT4 receptor stimulation on basal and electrically evoked release of acetylcholine from Guinea-pig myenteric plexus","volume":"345","author":"Kilbinger","year":"1992","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"issue":"9","key":"10.1016\/bs.pbr.2022.01.013_bb0625","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.tips.2008.07.001","article-title":"A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory","volume":"29","author":"King","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0630","first-page":"120","article-title":"Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease","volume":"131","author":"Kish","year":"2008","journal-title":"Brain"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0635","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00726-005-0162-4","article-title":"Peculiarities of L-DOPA treatment of Parkinson's disease","volume":"28","author":"Kostrzewa","year":"2005","journal-title":"Amino Acids"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0640","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ejn.13354","article-title":"Reducing falls in Parkinson's disease: interactions between donepezil and the 5-HT6 receptor antagonist idalopirdine on falls in a rat model of impaired cognitive control of complex movements","volume":"45","author":"Kucinski","year":"2017","journal-title":"Eur. J. Neurosci."},{"issue":"1\u20132","key":"10.1016\/bs.pbr.2022.01.013_bb0645","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0014-2999(95)00850-0","article-title":"SDZ NVI 085, an \u03b11A-adrenoceptor agonist with 5-HT2A receptor antagonist properties","volume":"297","author":"Lachnit","year":"1996","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0650","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/syn.10288","article-title":"5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex","volume":"51","author":"Lacroix","year":"2004","journal-title":"Synapse"},{"issue":"8","key":"10.1016\/bs.pbr.2022.01.013_bb0655","doi-asserted-by":"crossref","first-page":"781","DOI":"10.4155\/fmc-2017-0031","article-title":"Modulating 5-HT(4) and 5-HT(6) receptors in Alzheimer's disease treatment","volume":"9","author":"Lalut","year":"2017","journal-title":"Future Med. Chem."},{"issue":"7","key":"10.1016\/bs.pbr.2022.01.013_bb0660","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0028-3908(01)00123-X","article-title":"Enhancement of place and object recognition memory in young adult and old rats by RS 67333, a partial agonist of 5-HT4 receptors","volume":"41","author":"Lamirault","year":"2001","journal-title":"Neuropharmcology"},{"key":"10.1016\/bs.pbr.2022.01.013_bb0665","article-title":"Idalopirdine: another disappointment for people with dementia","volume":"360","author":"Le Couteur","year":"2018","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0670","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2147\/nedt.2006.2.4.455","article-title":"Atomoxetine: a novel treatment for child and adult ADHD","volume":"2","author":"Ledbetter","year":"2006","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"7","key":"10.1016\/bs.pbr.2022.01.013_bb0675","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/mds.25003","article-title":"Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms","volume":"27","author":"Lee","year":"2012","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/bs.pbr.2022.01.013_bb0680","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1021\/cn500340j","article-title":"Serotonergic regulation of prefrontal cortical circuitries involved in cognitive processing: a review of individual 5-HT receptor mechanisms and concerted effects of 5-HT receptors exemplified by the multimodal antidepressant vortioxetine","volume":"6","author":"Leiser","year":"2015","journal-title":"ACS Chem. Nerosci."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0685","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0197-4580(01)00221-4","article-title":"Increased alpha 2-adrenergic receptor binding in locus coeruleus projection areas in dementia with Lewy bodies","volume":"22","author":"Leverenz","year":"2001","journal-title":"Neurobiol. Aging"},{"issue":"10","key":"10.1016\/bs.pbr.2022.01.013_bb0690","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/mds.25104","article-title":"Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease","volume":"27","author":"Lewis","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.pbr.2022.01.013_bb0695","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.brainres.2006.11.060","article-title":"5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus","volume":"1134","author":"Li","year":"2007","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0700","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2002.tb00221.x","article-title":"Galantamine\u2014a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease","volume":"8","author":"Lilienfeld","year":"2002","journal-title":"CNS Drug Rev."},{"issue":"9","key":"10.1016\/bs.pbr.2022.01.013_bb0705","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s11055-008-9077-3","article-title":"Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial)","volume":"38","author":"Litvinenko","year":"2008","journal-title":"Neurosci. Behav. Physiol."},{"issue":"20","key":"10.1016\/bs.pbr.2022.01.013_bb0710","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1212\/WNL.0b013e318292a31d","article-title":"Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD","volume":"80","author":"Loane","year":"2013","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0715","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/WCO.0000000000000218","article-title":"Apathy and noradrenaline: silent partners to mild cognitive impairment in Parkinson's disease?","volume":"28","author":"Loued-Khenissi","year":"2015","journal-title":"Curr. Opin. Neurol."},{"issue":"6","key":"10.1016\/bs.pbr.2022.01.013_bb0720","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.neuropharm.2005.01.007","article-title":"Analysis of the role of 5-HT1A receptors in spatial and aversive learning in the rat","volume":"48","author":"L\u00fcttgen","year":"2005","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0725","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jchemneu.2004.09.001","article-title":"5-HT1A receptor mRNA and immunoreactivity in the rat medial septum\/diagonal band of Broca\u2014relationships to GABAergic and cholinergic neurons","volume":"29","author":"L\u00fcttgen","year":"2005","journal-title":"J. Chem. Neuroanat."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0730","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1471-4159.1978.tb10792.x","article-title":"Regional distribution of monoamines and their metabolites in the human brain","volume":"30","author":"Mackay","year":"1978","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0735","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/jpet.105.092262","article-title":"5-Hydroxytryptamine 1A receptor blockade facilitates aversive learning in mice: interactions with cholinergic and glutamatergic mechanisms","volume":"316","author":"Madjid","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"Pt 9","key":"10.1016\/bs.pbr.2022.01.013_bb0740","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/brain\/aww162","article-title":"The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease","volume":"139","author":"Maillet","year":"2016","journal-title":"Brain"},{"issue":"5","key":"10.1016\/bs.pbr.2022.01.013_bb0745","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1460-9568.2006.05003.x","article-title":"Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release","volume":"24","author":"Marcos","year":"2006","journal-title":"Eur. J. Neurosci."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0750","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0304-3940(98)00928-8","article-title":"Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease","volume":"260","author":"Marie","year":"1999","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0755","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/mds.22307","article-title":"Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study","volume":"24","author":"Marsh","year":"2009","journal-title":"Mov. Disord."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0760","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1476-5381.1992.tb14306.x","article-title":"Opposing roles for 5-HT1B and 5-HT3 receptors in the control of 5-HT release in rat hippocampus in vivo","volume":"106","author":"Martin","year":"1992","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0765","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0022-3565(24)38802-0","article-title":"Evidence for involvement of central 5-HT(4) receptors in cholinergic function associated with cognitive processes: behavioral, electrophysiological, and neurochemical studies","volume":"296","author":"Matsumoto","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"S17","key":"10.1016\/bs.pbr.2022.01.013_bb0770","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1192\/S0007125000296876","article-title":"The importance of serotonin-dopamine interactions in the action of clozapine","volume":"160","author":"Meltzer","year":"1992","journal-title":"Br. J. Psychiatry"},{"issue":"6","key":"10.1016\/bs.pbr.2022.01.013_bb0775","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1515\/revneuro-2013-0026","article-title":"5-HT systems: emergent targets for memory formation and memory alterations","volume":"24","author":"Meneses","year":"2013","journal-title":"Rev. Neurosci."},{"issue":"12","key":"10.1016\/bs.pbr.2022.01.013_bb0780","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1517\/14656566.8.12.1941","article-title":"Apomorphine in the treatment of Parkinson's disease","volume":"8","author":"Menon","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0785","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cne.902750205","article-title":"Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: observations based on the distribution of acetylcholinesterase and choline acetyltransferase","volume":"275","author":"Mesulam","year":"1988","journal-title":"J. Comp. Neurol."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0790","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.brainres.2006.08.108","article-title":"Cognitive effects of SL65.0155, a serotonin 5-HT4 receptor partial agonist, in animal models of amnesia","volume":"1121","author":"Micale","year":"2006","journal-title":"Brain Res."},{"issue":"24","key":"10.1016\/bs.pbr.2022.01.013_bb0795","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1212\/WNL.0b013e318278fe32","article-title":"Lewy pathology is not the first sign of degeneration in vulnerable neurons in Parkinson disease","volume":"79","author":"Milber","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0800","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pharmthera.2010.06.002","article-title":"From the cell to the clinic: a comparative review of the partial D2\/D3 receptor agonist and \u03b12-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease","volume":"128","author":"Millan","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/bs.pbr.2022.01.013_bb0805","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0028-3908(98)00078-1","article-title":"Serotonin (5-HT) 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo","volume":"37","author":"Millan","year":"1998","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0810","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1124\/jpet.104.069625","article-title":"The serotonin1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis","volume":"311","author":"Millan","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0815","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/jnr.490360304","article-title":"Serotonin-containing terminals synapse on septohippocampal neurons in the rat","volume":"36","author":"Milner","year":"1993","journal-title":"J. Neurosci. Res."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0820","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.npp.1300024","article-title":"Selective 5-HT1A antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat","volume":"28","author":"Misane","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0825","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2885.2008.00944.x","article-title":"Serotonin: a review","volume":"31","author":"Mohammad-Zadeh","year":"2008","journal-title":"J. Vet. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0830","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.neuropharm.2007.06.016","article-title":"VRX-03011, a novel 5-HT4 agonist, enhances memory and hippocampal acetylcholine efflux","volume":"53","author":"Mohler","year":"2007","journal-title":"Neuropharmacology"},{"issue":"6 Suppl","key":"10.1016\/bs.pbr.2022.01.013_bb0835","first-page":"3s","article-title":"Serotonergic neuronal systems: what their anatomic organization tells us about function","volume":"7","author":"Molliver","year":"1987","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0840","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/jpet.102.034249","article-title":"SL65. 0155, a novel 5-hydroxytryptamine4 receptor partial agonist with potent cognition-enhancing properties","volume":"302","author":"Moser","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/bs.pbr.2022.01.013_bb0845","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cnr.2006.09.006","article-title":"Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson's disease","volume":"6","author":"Mosley","year":"2006","journal-title":"Clin. Neurosci. Res."},{"issue":"5","key":"10.1016\/bs.pbr.2022.01.013_bb0850","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/ana.410150503","article-title":"Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease","volume":"15","author":"Nakano","year":"1984","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/bs.pbr.2022.01.013_bb0855","first-page":"802","article-title":"The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives","volume":"11","author":"Newman-Tancredi","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0860","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/jpet.102.039883","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2, receptor subtypes","volume":"303","author":"Newman-Tancredi","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/bs.pbr.2022.01.013_bb0865","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1021\/cr078224o","article-title":"Serotonin receptors","volume":"108","author":"Nichols","year":"2008","journal-title":"Chem. Rev."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0870","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0014-2999(79)90492-8","article-title":"Interactions between serotonergic and dopaminergic systems in rat brain demonstrated by small unilateral lesions of the raphe nuclei","volume":"57","author":"Nicolaou","year":"1979","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0875","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbr.2008.02.023","article-title":"The role of 5-HT(1A) receptors in learning and memory","volume":"195","author":"Ogren","year":"2008","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0880","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbr.2008.02.023","article-title":"The role of 5-HT1A receptors in learning and memory","volume":"195","author":"\u00d6gren","year":"2008","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0885","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1037\/0894-4105.9.1.126","article-title":"Dopamine-dependent frontostriatal planning deficits in early Parkinson's disease","volume":"9","author":"Owen","year":"1995","journal-title":"Neuropsychology"},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0890","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.parkreldis.2013.11.017","article-title":"Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease","volume":"20","author":"Pagonabarraga","year":"2014","journal-title":"Parkinsonism Relat. Disord."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0895","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jchemneu.2011.04.005","article-title":"Serotonin innervation of basal ganglia in monkeys and humans","volume":"41","author":"Parent","year":"2011","journal-title":"J. Chem. Neuroanat."},{"issue":"5","key":"10.1016\/bs.pbr.2022.01.013_bb0900","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0361-9230(77)90066-1","article-title":"Dorsal raphe, substantia nigra and locus coeruleus: interconnections with each other and the neostriatum","volume":"2","author":"Pasquier","year":"1977","journal-title":"Brain Res. Bull."},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0905","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.neuroimage.2011.03.012","article-title":"Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study","volume":"56","author":"Pavese","year":"2011","journal-title":"NeurImage"},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0910","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.pbb.2005.05.005","article-title":"Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task","volume":"81","author":"Perez-Garc\u00eda","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"3\u20134","key":"10.1016\/bs.pbr.2022.01.013_bb0915","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0028-3908(94)90060-4","article-title":"The molecular evolution of G protein-coupled receptors: focus on 5-hydroxytryptamine receptors","volume":"33","author":"Peroutka","year":"1994","journal-title":"Neuropharmacology"},{"issue":"13","key":"10.1016\/bs.pbr.2022.01.013_bb0920","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/mds.25109","article-title":"Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms","volume":"27","author":"Pifl","year":"2012","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb0925","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/mds.20700","article-title":"Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study","volume":"21","author":"Poewe","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.pbr.2022.01.013_bb0930","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbr.2014.07.037","article-title":"Serotonin in Parkinson's disease","volume":"277","author":"Politis","year":"2015","journal-title":"Behav. Brain Res."},{"issue":"5","key":"10.1016\/bs.pbr.2022.01.013_bb0935","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000100850","article-title":"Cognitive changes in Parkinson's disease patients with visual hallucinations","volume":"23","author":"Ramirez-Ruiz","year":"2007","journal-title":"Dement. Geriatr. Cogn. Disord."},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb0940","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0024-3205(77)90514-8","article-title":"Neurotransmitter receptor alterations in Parkinson's disease","volume":"21","author":"Reisine","year":"1977","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0945","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF02246088","article-title":"Combined treatment with a 5HT1A receptor agonist and a muscarinic acetylcholine receptor antagonist disrupts water maze navigation behavior","volume":"122","author":"Riekkinen","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"issue":"7","key":"10.1016\/bs.pbr.2022.01.013_bb0950","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1021\/jm021085c","article-title":"Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-Bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist","volume":"46","author":"Riemer","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/bs.pbr.2022.01.013_bb0955","first-page":"325","article-title":"Neuronal loss in the substantia nigra in patients with Alzheimer's disease and Parkinson's disease in relation to extrapyramidal symptoms and dementia","volume":"317","author":"Rinne","year":"1989","journal-title":"Prog. Clin. Bil. Res."},{"issue":"suppl_1","key":"10.1016\/bs.pbr.2022.01.013_bb0960","doi-asserted-by":"crossref","first-page":"i151","DOI":"10.1093\/cercor\/bhm066","article-title":"Differential regulation of fronto-executive function by the monoamines and acetylcholine","volume":"17","author":"Robbins","year":"2007","journal-title":"Cereb. Cortex"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0965","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s002130100840","article-title":"5-HT6 receptor antagonists enhance retention of a water maze task in the rat","volume":"158","author":"Rogers","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb0970","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/ana.410170210","article-title":"The nucleus basalis of Meynert in neurological disease: a quantitative morphological study","volume":"17","author":"Rogers","year":"1985","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/bs.pbr.2022.01.013_bb0975","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/brain\/awn112","article-title":"Parkinson's disease and dopaminergic therapy\u2014differential effects on movement, reward and cognition","volume":"131","author":"Rowe","year":"2008","journal-title":"Brain"},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb0980","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1017\/S1041610209990184","article-title":"Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors","volume":"22","author":"Rozzini","year":"2010","journal-title":"Int. Psychogeriatr."},{"issue":"8","key":"10.1016\/bs.pbr.2022.01.013_bb0985","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1002\/hbm.25393","article-title":"The default mode network and cognition in Parkinson's disease: a multimodal resting-state network approach","volume":"42","author":"Ruppert","year":"2021","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/bs.pbr.2022.01.013_bb0990","doi-asserted-by":"crossref","first-page":"107872","DOI":"10.1016\/j.pharmthera.2021.107872","article-title":"Biased agonism in drug discovery: is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?","volume":"227","author":"Sa\u0142aciak","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/bs.pbr.2022.01.013_bb0995","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb1000","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0006-8993(85)90385-3","article-title":"Antidromic activation of dorsal raphe neurons from neostriatum: physiological characterization and effects of terminal autoreceptor activation","volume":"332","author":"Sawyer","year":"1985","journal-title":"Brain Res."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb1005","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0006-8993(83)90993-9","article-title":"Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease","volume":"275","author":"Scatton","year":"1983","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb1010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00210-008-0341-4","article-title":"The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease","volume":"379","author":"Scheller","year":"2009","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/bs.pbr.2022.01.013_bb1015","doi-asserted-by":"crossref","first-page":"113514","DOI":"10.1016\/j.expneurol.2020.113514","article-title":"A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease","volume":"335","author":"Schneider","year":"2021","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb1020","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/mds.27602","article-title":"Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review","volume":"34","author":"Seppi","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.pbr.2022.01.013_bb1025","series-title":"Handbook of Behavioral Neuroscience","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-7339(10)70081-3","article-title":"CHAPTER 2.6 - serotonergic feedback control","author":"Sharp","year":"2010"},{"key":"10.1016\/bs.pbr.2022.01.013_bb1030","doi-asserted-by":"crossref","first-page":"108155","DOI":"10.1016\/j.neuropharm.2020.108155","article-title":"Central 5-HT receptors and their function; present and future","volume":"177","author":"Sharp","year":"2020","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb1035","first-page":"1","article-title":"Improving the treatment of Parkinson's disease: a novel approach by modulating 5-HT1A receptors","volume":"4","author":"Shimizu","year":"2013","journal-title":"Aging Dis."},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb1040","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/00001756-199902250-00019","article-title":"5-HT4 receptor modulation of acetylcholine outflow in Guinea pig brain slices","volume":"10","author":"Siniscalchi","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/bs.pbr.2022.01.013_bb1045","doi-asserted-by":"crossref","DOI":"10.1097\/00008877-199908001-00220","article-title":"5-HT6 receptors: functional correlates and potential therapeutic indications","volume":"10","author":"Sleight","year":"1999","journal-title":"Behav. Pharmacol."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb1050","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1124\/jpet.109.156349","article-title":"Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine2A receptor inverse agonist","volume":"332","author":"Snigdha","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/bs.pbr.2022.01.013_bb1055","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1017\/S1092852916000602","article-title":"Parkinson's disease psychosis as a serotonin-dopamine imbalance syndrome","volume":"21","author":"Stahl","year":"2016","journal-title":"CNS Spectr."},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb1060","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0091-3057(01)00742-0","article-title":"Pharmacological profile of SB-357134: a potent, selective, brain penetrant, and orally active 5-HT6 receptor antagonist","volume":"71","author":"Stean","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb1065","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0166-4328(94)00157-B","article-title":"The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour","volume":"67","author":"Steckler","year":"1995","journal-title":"Behav. Brain Res."},{"issue":"9","key":"10.1016\/bs.pbr.2022.01.013_bb1070","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1176\/appi.ajp.2012.12030342","article-title":"Atypical antipsychotic use in patients with dementia: managing safety concerns","volume":"169","author":"Steinberg","year":"2012","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb1075","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0306-4522(81)90146-9","article-title":"Distribution of serotonin-immunoreactivity in the central nervous system of the rat\u2014cell bodies and terminals","volume":"6","author":"Steinbusch","year":"1981","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/bs.pbr.2022.01.013_bb1080","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/cne.903210403","article-title":"Afferent projections to the cholinergic pedunculopontine tegmental nucleus and adjacent midbrain extrapyramidal area in the albino rat. I. Retrograde tracing studies","volume":"321","author":"Steininger","year":"1992","journal-title":"J. Comp. Neurol."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb1085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00415-010-5666-5","article-title":"Preserved serotonin transporter binding in de novo Parkinson's disease: negative correlation with the dopamine transporter","volume":"258","author":"Strecker","year":"2011","journal-title":"J. Neurol."},{"issue":"1\u20133","key":"10.1016\/bs.pbr.2022.01.013_bb1090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.schres.2007.06.008","article-title":"Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"95","author":"Sumiyoshi","year":"2007","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/bs.pbr.2022.01.013_bb1095","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1474-4422(12)70152-7","article-title":"Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment","volume":"11","author":"Svenningsson","year":"2012","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb1100","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1523\/JNEUROSCI.4265-05.2006","article-title":"Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies","volume":"26","author":"Szot","year":"2006","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb1105","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1600-0404.1984.tb00798.x","article-title":"The basal nucleus of Meynert in idiopathic Parkinson's disease","volume":"70","author":"Tagliavini","year":"1984","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb1110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.tips.2012.12.002","article-title":"Recent developments in 5-HT3 receptor pharmacology","volume":"34","author":"Thompson","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb1115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1749-6632.1990.tb16870.x","article-title":"Anatomy of the serotonergic system","volume":"600","author":"T\u00f5rk","year":"1990","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb1120","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/mds.27204","article-title":"APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease","volume":"33","author":"Tropea","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.pbr.2022.01.013_bb1125","series-title":"Neuropathology of Drug Addictions and Substance Misuse","article-title":"Chapter 73 - neurobiology of the effects of psilocybin in relation to its potential therapeutic targets","author":"Tyls","year":"2016"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb1130","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.mp.4001763","article-title":"Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine","volume":"11","author":"Tzavara","year":"2006","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb1135","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.28360","article-title":"Cholinergic denervation patterns across cognitive domains in Parkinson's disease","volume":"36","author":"van der Zee","year":"2021","journal-title":"Mov. Disord."},{"key":"10.1016\/bs.pbr.2022.01.013_bb1140","series-title":"Pharmacochemistry Library","article-title":"5-HT1A receptor ligands","author":"Van Wijngaarden","year":"1997"},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb1145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0166-4328(87)90241-5","article-title":"Near-total loss of 'learning' and 'memory' as a result of combined cholinergic and serotonergic blockade in the rat","volume":"23","author":"Vanderwolf","year":"1987","journal-title":"Behav. Brain Res."},{"key":"10.1016\/bs.pbr.2022.01.013_bb1150","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fnbeh.2012.00048","article-title":"The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease","volume":"6","author":"Vazey","year":"2012","journal-title":"Front Behav. Neurosci."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb1155","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/cne.903400103","article-title":"Projections of the dorsal raphe nucleus to the brainstem: PHA-L analysis in the rat","volume":"340","author":"Vertes","year":"1994","journal-title":"J. Comp. Neurol."},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb1160","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nn1846","article-title":"Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory","volume":"10","author":"Vijayraghavan","year":"2007","journal-title":"Nat. Neurosci."},{"issue":"8","key":"10.1016\/bs.pbr.2022.01.013_bb1165","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/j.1460-9568.2011.07621.x","article-title":"Serotonin innervation of human basal ganglia","volume":"33","author":"Wallman","year":"2011","journal-title":"Eur. J. Neurosci."},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb1170","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0306-4522(99)00605-3","article-title":"Synaptic contacts between serotonergic and cholinergic neurons in the rat dorsal raphe nucleus and laterodorsal tegmental nucleus","volume":"97","author":"Wang","year":"2000","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb1175","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jnnp-2014-307659","article-title":"Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis","volume":"86","author":"Wang","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"12","key":"10.1016\/bs.pbr.2022.01.013_bb1180","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/mds.25641","article-title":"Cortical and subcortical brain atrophy in Parkinson's disease with visual hallucination","volume":"28","author":"Watanabe","year":"2013","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/bs.pbr.2022.01.013_bb1185","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1212\/WNL.0b013e3181ebdd79","article-title":"Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease","volume":"75","author":"Weintraub","year":"2010","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb1190","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ana.410130304","article-title":"Basal forebrain neurons in the dementia of Parkinson disease","volume":"13","author":"Whitehouse","year":"1983","journal-title":"Ann. Neurol."},{"issue":"10","key":"10.1016\/bs.pbr.2022.01.013_bb1195","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S1474-4422(05)70146-0","article-title":"Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study","volume":"4","author":"Williams","year":"2005","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/bs.pbr.2022.01.013_bb1200","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200620060-00004","article-title":"Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options","volume":"20","author":"Williams-Gray","year":"2006","journal-title":"CNS Drugs"},{"issue":"3555","key":"10.1016\/bs.pbr.2022.01.013_bb1205","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1126\/science.139.3555.610","article-title":"Alteration in learning ability caused by changes in cerebral serotonin and catechol amines","volume":"139","author":"Woolley","year":"1963","journal-title":"Science"},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb1210","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0028-3908(01)00056-9","article-title":"A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze","volume":"41","author":"Woolley","year":"2001","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb1215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2012.02.002","article-title":"Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease","volume":"97","author":"Xu","year":"2012","journal-title":"Prog. Neurobiol."},{"issue":"3","key":"10.1016\/bs.pbr.2022.01.013_bb1220","first-page":"349","article-title":"Exendin-4, an analogue of glucagon-like peptide-1, attenuates hyperalgesia through serotonergic pathways in rats with neonatal colonic sensitivity","volume":"65","author":"Yang","year":"2014","journal-title":"J. Physiol. Pharmacol."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb1225","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1023\/A:1010257808945","article-title":"The midbrain dopaminergic system: anatomy and genetic variation in dopamine neuron number of inbred mouse strains","volume":"31","author":"Zaborszky","year":"2001","journal-title":"Behav. Genet."},{"key":"10.1016\/bs.pbr.2022.01.013_bb1230","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-4757-0145-6_2","article-title":"Afferents to basal forebrain cholinergic projection neurons: an update","volume":"295","author":"Z\u00e1borszky","year":"1991","journal-title":"Adv. Exp. Med. Biol."},{"issue":"2","key":"10.1016\/bs.pbr.2022.01.013_bb1235","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3233\/JPD-191768","article-title":"The novel dual GLP-1\/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of Parkinson's disease","volume":"10","author":"Zhang","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/bs.pbr.2022.01.013_bb1240","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbr.2014.09.016","article-title":"The role of lateral habenula\u2013dorsal raphe nucleus circuits in higher brain functions and psychiatric illness","volume":"277","author":"Zhao","year":"2015","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/bs.pbr.2022.01.013_bb1245","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.410260106","article-title":"The pedunculopontine nucleus in Parkinson's disease","volume":"26","author":"Zweig","year":"1989","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/bs.pbr.2022.01.013_bb1250","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1212\/WNL.43.5.986","article-title":"The locus ceruleus and dementia in Parkinson's disease","volume":"43","author":"Zweig","year":"1993","journal-title":"Neurology"}],"container-title":["Progress in Brain Research","Cognition in Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612322000139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079612322000139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T04:28:06Z","timestamp":1762230486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079612322000139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323901642"],"references-count":249,"URL":"https:\/\/doi.org\/10.1016\/bs.pbr.2022.01.013","relation":{},"ISSN":["0079-6123"],"issn-type":[{"value":"0079-6123","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}